Fig. 1From: Phase II study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancerKaplan-Meier estimates of the progression-free survival (PFS) and overall survival (OS). a The median PFS was 9.5 months (95% CI: 7.8–12.6 months). b The median OS was 20.2 months (95% CI: 15.0–25.4 months)Back to article page